

APPENDIX 4D HALF YEAR REPORT

Tyrian Diagnostics Limited
ACN 080 277 998

Current Reporting Period	Half Year ended 31 December 2015
Previous corresponding period	Half Year ended 31 December 2014

Results for announcement to the market				\$'000
Revenue from continuing activities	Decreased	59 %	to	11
Revenue and other income from continuing activities	Decreased	59 %	to	11
Loss from continuing activities after tax attributable to members	Decreased	9 %	to	147
Loss for the period attributable to members	Decreased	9 %	to	147

Dividends/distributions	Amount per security	Franked amount per security
Final dividend	Nil	Nil
Interim dividend	Nil	Nil

Record date for determining entitlements to the interim dividend	N/A
--	-----

NTA Backing

	31 December 2015	31 December 2014
Net tangible asset backing per ordinary share (cents)	0.04 cent	0.07 cent

A Review of operations is included in the Directors' Report of the attached Half Year Report of Tyrian Diagnostics Limited.

This Appendix 4D is based on Financial Reports which have been subject to review.

Tyrian Diagnostics Limited
Interim Financial Report – 31 December 2015
ACN 080 277 998

Contents

Directors' report	3
Auditor's independence declaration	5
Statement of comprehensive income	6
Statement of financial position	7
Statement of changes in equity	8
Statement of cash flows	9
Notes to the financial statements	10
Directors' declaration	12
Independent auditor's review report to the members	13

The interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2015 and any public announcements made by Tyrian Diagnostics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

Tyrian Diagnostics Limited
Directors' report
For the half-year ended 31 December 2015

The Directors of Tyrian Diagnostics Limited (the "Company") present their report on the Company for the half-year to 31 December 2015.

Directors

The following persons were directors of Tyrian Diagnostics Limited during the whole of the half-year to 31 December 2015 and up to the date of this report:

Roger Amos (Chairman)
Caroline Popper (Resigned 23 February 2016)
Meryllyn Sleight
Simon O'Loughlin (Appointed 23 February 2016)

Principal activities

During the half-year the principal continuing activities of the Company consisted of:

- a) Business development activities related to the commercialisation of the Company's TB intellectual property including engaging with suitable partners to licence the Company's patented molecular TB biomarker for development and commercialisation of tests to diagnose active TB;
- b) Seeking and engaging with partners to further develop the Company's proprietary DiagnostIQ platform for diagnostic testing;
- c) During the half-year the Company has been actively involved in assessing a number of opportunities to maximise the value of the Company's assets for the benefit of shareholders.

Comments on the operations and the results of those operations are set out below.

REVIEW AND RESULTS OF OPERATIONS

Results

Revenue and Other Income from continuing operations to 31 December 2015 was \$11,325 (\$27,816 to 31 December 2014). The net loss after tax in the half-year to 31 December 2015 was \$147,268 (\$162,656 to 31 December 2014).

Cash Used in Operations

Net cash outflows from operating activities increased from \$109,200 in the previous corresponding period to \$176,239 in the current half-year.

Operations Review

Strategic Opportunities

The Company working with its advisors, TC Corporate, has been actively involved in identifying and assessing a number of corporate opportunities to maximise the value of the Company's remaining assets for the benefit of shareholders.

Commercialising the TB Intellectual Property

Tyrian continues in its management of licences of its TB intellectual property for rapid protein and molecular diagnostic tests to companies developing new point-of-care diagnostic platforms with higher sensitivity of detection than current technologies.

Commercialising Tyrian's DiagnostIQ Technology

During 2012 an agreement was reached with Australian diagnostic company Agenix Limited for a licence to the use of DiagnostIQ for medical applications. Terms for the licence required payment to Tyrian of Agenix shares, valued at a total of \$500,000 at time of issue. Shares were issued to Tyrian in instalments up to June 2014 and the last of these shares were sold in the previous corresponding half-year.

SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS

There have been no significant changes in the state of affairs of the Company during the half-year ended 31 December 2015.

SIGNIFICANT EVENTS AFTER THE BALANCE DATE

The Company is not aware of any matter or circumstance that has arisen since 31 December 2015 that has significantly affected, or may significantly affect:

- (a) the Company's operations in future financial years, or
- (b) the results of those operations in future financial years, or
- (c) the Company's state of affairs in future financial years.

LIKELY DEVELOPMENTS AND EXPECTED RESULTS

Any further information on likely developments in the operations of the Company and the expected results of operations have not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the Company.

AUDITOR'S INDEPENDENCE DECLARATION

A copy of the auditors' independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 5.

This report is made in accordance with a resolution of the directors.



Roger Amos
Chairman

Sydney
24 February 2016

AUDITOR'S INDEPENDENCE DECLARATION

To the Directors of Tyrian Diagnostics Limited

As lead auditor for the review of the financial report of Tyrian Diagnostics Limited for the half-year ended 31 December 2015 I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (a) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (b) any applicable code of professional conduct in relation to the review.



**Sydney, NSW
24 February 2016**

**A G Smith
Director**

HLB Mann Judd Assurance (NSW) Pty Ltd ABN 96 153 077 215

Level 19 207 Kent Street Sydney NSW 2000 Australia | Telephone +61 (0)2 9020 4000 | Fax +61 (0)2 9020 4190

Email: mailbox@hlbnsw.com.au | Website: www.hlb.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

Tyrian Diagnostics Limited
Statement of comprehensive income
For the half-year ended 31 December 2015

		Half-year	
	Notes	2015 \$	2014 \$
Revenue from continuing operations		11,325	27,816
Corporate & administration expenses		(155,923)	(168,147)
Patent costs		(2,670)	(22,325)
		<hr/>	
Profit/(Loss) before income tax		(147,268)	(162,656)
Income tax expense		-	-
		<hr/>	
Profit/(Loss) from continuing operations		(147,268)	(162,656)
		<hr/>	
Profit/(Loss) for the half year attributable to members of Tyrian Diagnostics Limited		(147,268)	(162,656)
		<hr/>	
Total comprehensive profit/(loss) attributable to members of Tyrian Diagnostics Limited		(147,268)	(162,656)
		<hr/>	

Earnings per share from continuing operations attributable to the ordinary equity holders of the Company:			
	Cents		Cents
Basic earnings per share	0.0		0.0
Diluted earnings per share	0.0		0.0
Earnings per share attributable to the ordinary equity holders of the Company:			
	Cents		Cents
Basic earnings per share	0.0		0.0
Diluted earnings per share	0.0		0.0

The above Statement of comprehensive income should be read in conjunction with the accompanying notes.

Tyrian Diagnostics Limited
Statement of financial position
31 December 2015

	Notes	31 December 2015 \$	30 June 2015 \$
ASSETS			
Current assets			
Cash and cash equivalents		407,795	584,034
Other assets		29,913	12,055
Total current assets		<u>437,708</u>	<u>596,089</u>
Total assets		<u>437,708</u>	<u>596,089</u>
LIABILITIES			
Current liabilities			
Trade and other payables		26,517	37,630
Total current liabilities		<u>26,517</u>	<u>37,630</u>
Total liabilities		<u>26,517</u>	<u>37,630</u>
Net assets		<u>411,191</u>	<u>558,459</u>
EQUITY			
Contributed equity	3	123,625,663	123,625,663
Reserves		3,798,735	3,798,735
Accumulated losses		<u>(127,013,207)</u>	<u>(126,865,939)</u>
Total equity		<u>411,191</u>	<u>558,459</u>

The above Statement of financial position should be read in conjunction with the accompanying notes.

Tyrian Diagnostics Limited
Statement of changes in equity
For the half-year ended 31 December 2015

	Attributable to owners of Tyrian Diagnostics Limited			
	Contributed Equity \$	Reserves \$	Accumulated Losses \$	Total Equity \$
Balance at 1 July 2014	123,625,663	3,798,735	(126,560,315)	864,083
Loss for the half-year	-	-	(162,656)	(162,656)
Total comprehensive loss for the half-year	-	-	(162,656)	(162,656)
Balance at 31 December 2014	123,625,663	3,798,735	(126,722,971)	701,427
Balance at 1 July 2015	123,625,663	3,798,735	(126,865,939)	558,459
Loss for the half-year	-	-	(147,268)	(147,268)
Total comprehensive loss for the half-year	-	-	(147,268)	(147,268)
Balance at 31 December 2015	123,625,663	3,798,735	(127,013,207)	411,191

The above Statement of changes in equity should be read in conjunction with the accompanying notes.

Tyrian Diagnostics Limited
Statement of cash flows
For the half-year ended 31 December 2015

	Notes	Half-year 2015 \$	2014 \$
Cash flows from operating activities			
Receipts from customers (inclusive of goods and services tax)		5,355	82,872
Payments to suppliers and employees (inclusive of goods and services tax)		(187,564)	(201,722)
		(182,209)	(118,850)
Interest received		5,970	9,650
Net cash outflow from operating activities		(176,239)	(109,200)
Net increase (decrease) in cash and cash equivalents		(176,239)	(109,200)
Cash and cash equivalents at the beginning of the half-year		584,034	815,662
Cash and cash equivalents at end of the half-year		407,795	706,462

The above Statement of cash flows should be read in conjunction with the accompanying notes.

1 Summary of significant accounting policies

These general purpose financial statements for the interim half year reporting period ended 31 December 2015 have been prepared in accordance with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2015 and any public announcements made by Tyrian Diagnostics Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The accounting policies adopted are consistent with those of the previous financial year and the corresponding interim reporting period.

(a) Basis of preparation of half-year financial report

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

Critical accounting estimates

The preparation of financial statements in conformity with AIFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies. There are no estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities.

Historical cost convention

These financial statements have been prepared under the historical cost convention, as modified by certain financial assets and liabilities (including derivative instruments) at fair value through profit or loss.

Going Concern

During the period ended 31 December 2015 the Company incurred a loss from continuing operations before tax of \$147,268 (2014: \$162,656) and net cash outflows from operating activities of \$176,239 (2014: \$109,200).

Having regard to cash-flow forecasts prepared by the Company, the directors believe the Company will continue as a going concern for a period of 12 months from the date of the Directors' Report. The financial statements have therefore been prepared on a going concern basis.

2 Segment reporting

AASB 8 *Operating Segments* requires a 'management approach' under which segment information is presented on the same basis as that used for internal reporting to key decision makers to evaluate segment performance and decide how to allocate resources to segments. This has resulted in the Company being considered as one reportable segment.

Operating segments are reported in a manner that is consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision-maker has been identified as the Board of directors.

3 Contributed equity

Movements in ordinary share capital:

Details	Number of shares	\$
Balance at 1 January 2015	1,022,027,092	123,625,663
Balance as at 30 June 2015	1,022,027,092	123,625,663
Balance as at 31 December 2015	1,022,027,092	123,625,663

4 Events occurring after the balance sheet date

The Company is not aware of any matters or circumstances which are not otherwise dealt with in the financial statements that have significantly, or may significantly, affect the operations of the Company, the results of its operations or the state of the Company in subsequent years.

Tyrian Diagnostics Limited
Directors' Declaration
31 December 2015

In the directors' opinion:

- a. the financial statements and notes set out on pages 6 to 11 are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with Accounting Standard 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*; and
 - (ii) giving a true and fair view of the Company's financial position as at 31 December 2015 and of its performance for the half-year ended on that date; and
- b. there are reasonable grounds to believe that Tyrian Diagnostics Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



Roger Amos
Chairman

Sydney
24 February 2016

TYRIAN DIAGNOSTICS LIMITED**ACN 080 277 998****INDEPENDENT AUDITOR'S REVIEW REPORT**

To the members of Tyrian Diagnostics Limited:

We have reviewed the accompanying half-year financial report of Tyrian Diagnostics Limited ("the Company"), which comprises the statement of financial position as at 31 December 2015, the statement of comprehensive income, the statement of changes in equity and the statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Half-Year Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the Company's financial position as 31 December 2015 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of the Company ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Our review did not involve an analysis of the prudence of business decisions made by directors or management.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

HLB Mann Judd Assurance (NSW) Pty Ltd ABN 96 153 077 215

Level 19 207 Kent Street Sydney NSW 2000 Australia | Telephone +61 (0)2 9020 4000 | Fax +61 (0)2 9020 4190


Email: mailbox@hlbnsw.com.au | Website: www.hlb.com.au

Liability limited by a scheme approved under Professional Standards Legislation.

TYRIAN DIAGNOSTICS LIMITED**ACN 080 277 998****INDEPENDENT AUDITOR'S REVIEW REPORT (CONTINUED)****Conclusion**

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Tyrian Diagnostics Limited is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the Company's financial position as at 31 December 2015 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.



HLB Mann Judd Assurance (NSW) Pty Ltd
Chartered Accountants



A G Smith
Director

Sydney, NSW
24 February 2016